Fig. 5.

Effect of anti-CD19 mAb (pulse treatment) on B cell and T cell responses to myelin protein zero (P0). (a) Scatterplots showing the depletion of P0-specific plasmablasts (PB) by anti-CD19 mAb (n = 3, P < 0·0008). Gating strategy as described in Fig. 1a. (b) Data summary on the depletion of P0-reactive B cells by anti-CD19 mAb (n = 3). *P < 0·004 for P0-specific IgM⁺ B cells; **P < 0·0004 for P0-specific IgG⁺ B cells. (c) Treatment with anti-CD19 mAb did not alter splenocyte proliferation in response to P0 (180–199) and P0-extracellular domains (ECD (ECD) (n = 5 each, P > 0·05). Ovalbumin (OVA) was used as an irrelevant antigen. Data in (a–c) shown as mean ± standard error of the mean (s.e.m.) are from 8 weeks post-treatment initiation.